Nuzenio

Tradingview Tonix Pharmaceuticals

Tradingview Tonix Pharmaceuticals entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 7 latest news signals 1 publisher sources 100/100 entity strength

Latest news

TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingViewTradingView · Mon, 10 Aug 2026 14:19:14 GMTTNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingViewTradingView · Mon, 10 Aug 2026 13:32:08 GMTTNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - TradingViewTradingView · Mon, 10 Aug 2026 12:32:17 GMTTonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary - TradingViewTradingView · Mon, 10 Aug 2026 12:11:01 GMTTonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTTNXP: Q2 2026 revenue soared 575% year-over-year, driven by TONMYA sales and expanded coverage - TradingViewTradingView · Mon, 10 Aug 2026 11:08:44 GMTTonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMT

Timeline

Mon, 10 Aug 2026 14:19:14 GMTTNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Mon, 10 Aug 2026 13:32:08 GMTTNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Mon, 10 Aug 2026 12:32:17 GMTTNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - TradingView
Mon, 10 Aug 2026 12:11:01 GMTTonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary - TradingView
Mon, 10 Aug 2026 11:23:01 GMTTonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss - TradingView
Mon, 10 Aug 2026 11:08:44 GMTTNXP: Q2 2026 revenue soared 575% year-over-year, driven by TONMYA sales and expanded coverage - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Tonix Pharmaceuticals.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.